Cancer continues to be one of the top health issues facing us today. According to the Centers for Disease Control (CDC), cancer is the second leading cause of death in the United States behind heart disease. In the latest data available from the CDC, the agency notes that 595,930 Americans died in 2015 from cancer. It is a horrific illness that has impacted many of us and our loved ones. Unfortunately, experts do not see cancer wave stopping. In fact, many cancer groups are warning of massive growth in cancer cases in the years to come.

According to the American Cancer Society, there will be an estimated 1.74 million new cases of cancer that will occur in the U.S. this year alone. On a global scale, trends are showing an even stronger surge in cancer cases.

The American Cancer Society reported that there were 14.1 million new cases of cancer across the globe in 2012, which resulted in 8.2 million deaths. The cancer group estimates that by 2030, there could be as many as 21.7 million new cancer cases resulting in 13 million deaths globally. However, the group does admit that “the future burden will probably be even larger because of the adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and few childbirths, in economically developing countries,” according to their report.

The data highlights the desperate need to find a better way to fight cancer, rather than relying on outdated and painful treatments like chemotherapy.

Innovest Global, Inc. (OTC Pink: IVST) is one company that has a patented, next-generation cancer treatment technology that could help disrupt the industry.

Overview: Innovest Global, Inc. (OTC Pink: IVST) 

Innovest Global, Inc. is Cleveland, OH-based, diversified holding company. Currently, the company has two operational divisions: Biotechnology & Health Sciences and Commercial & Industrial.

The company’s Commercial & Industrial division has been the primary growth driver throughout 2018, with the Biotechnology & Health Sciences division officially coming online in July 2018.

Through the first half of 2018, Innovest Global has completed and integrated five acquisitions into its two divisions. The successful management team effectively led the company to three straight months of record revenues as a result of the successful acquisitions.

Innovest’s client base is a list of well-known and respected companies, agencies and institutions. Among Innovest Global’s client base includes: U.S. Navy, Cleveland Indians, University Hospitals, University of Louisiana, Byram Healthcare (a division of a Fortune 500 company), Iowa Department of Transportation, Houston Metro, Tarkette, and more.

IVST: Biotechnology & Health Sciences Division

In July 2018, Innovest Global closed on its acquisition of a 20% stake in StemVax Therapeutics, a translational biotechnology company. Adding to the exciting is the fact that StemVax Therapeutics is currently in the process of developing a cancer vaccine therapy to treat against brain tumors, specifically Glioblastomas (the same form of brain cancer as Arizona Senator John McCain).

StemVax Therapeutics’ flagship technology, the StemVax Glioblast (SVX-GB), is described as “a cancer vaccine, which is a medication that stimulates or restores the immune system’s ability to fight an existing cancer by strengthening the body’s natural defenses against the cancer cells. It is a meaningful technology, which could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors,” according to the company’s release.

Dr. Dwain Morris-Irvin, who is the President of Innovest’s Biotechnology & Health Sciences division, founded StemVax Therapeutics in 2014 and is currently the Chief Science Officer. Dr. Morris-Irvin has a decorated career as a neuro-scientist, who received his PhD in Pharmacology and Developmental Neuroscience with an emphasis on neural stem call fate and differentiation. Dr. Morris-Irvin even worked as an NIH/NINDS Post-Doctoral Fellow at the Dr. Anders Bjorklund Laboratory in Lund, Sweden.

StemVax Therapeutics Receives U.S. Patent For Cancer Vaccine Treatment Technology

Shortly after Innovest Global completed the acquisition of its stake in StemVax Therapeutics, the biotech company announced that its cancer vaccine technology has been awarded a U.S. Patent. The patent specifically related to “cancer antigens” and “treatment of cancer using vaccination therapy.”

“Patent approval is the trigger for us to engage major health organizations, to continue the progress toward the ‘StemVax Glioblast’ brain tumor vaccine going to market and improving people’s lives. After decades of research, it took nine years in the patent process, and is a transformational achievement,” said Dr. Dwain Morris-Irvin, President of Innovest’s Biotech Division. The patent application was initially filed back in 2008 by a hospital research organization, and was co-authored by Dr. Morris-Irvin, who is also the StemVax Chief Science Officer,” according to an Innovest Global corporate release.

On August 6, 2018, Innovest Global made a major announcement that it has signed an agreement with the highly-respected Cedars-Sinai Medical Center in Los Angeles, CA. In the agreement, Innovest has been awarded an exclusive worldwide license “for all of the intellectual property needed to commercialize the StemVax Glioblast brain tumor vaccine,” according to the press release. Cedars-Sinai Medical Center is a non-profit hospital that is widely considered to be one of the top hospitals and research organizations in the entire world.

This is a major step for Innovest Global’s biotech division and for the cancer vaccine treatment technology itself. With the backing of a patent, StemVax will now effectively prepare a market approach and begin reaching out to larger organizations for potential support. Overall, the patent is a major stamp of approval that StemVax is heading for great things.

IVST: Financials and First Half Accomplishments

Innovest Global is having a fantastic year thus far in 2018, as the accomplishments continue to rack up. During the second quarter, the conglomerate reported that sales grew 55.80% compared to the first quarter ($1.1 million in Q2 versus $708,804 in Q1), as current assets stand at $877,861 and cash holdings come in at $561,062.

As of the end of the second quarter 2018, Innovest Global holds no convertible debt, warrants, or options outstanding. This helps shareholders understand management is not turning to toxic debt to fund its growth strategy.

During the first quarter, Innovest Global received its first institutional shareholder in Winslow Asset Management. The Ohio-based asset manager purchased 10,000 shares during the first three months of 2018, according to a 13F filing. After an updated filing for the second quarter, it is confirmed that Winslow Asset Management continues to be long shares of Innovest Global. Winslow stayed put during the second quarter, not adding or selling their current position.

While there were certainly some enticing entry points that Winslow Asset Management could have used to engage in dollar-cost averaging during the second quarter, it is certainly a vote of confidence that the fund is remaining a bullish stance on Innovest.

Here is a complete list from a recent Innovest Global press release, which thoroughly highlighting the impressive achievements through the first half of 2018:

• Sales are up 55.8%. ($1,104,367 in Q2 compared to $708,804 in Q1). June Sales were highest ever, at 16.8% higher than May, the previous record.
• End Q2 current assets of $877,861 include cash on hand of $561,062.
• Our capital structure includes an unchanged free-trading float of 11,796,710 common shares. There are no convertible debts, no warrants or options outstanding.
• Our headcount is 44 employees, up from 26 at the start of the quarter.
• Our stock price is up 725% as of this past Friday, since our January 2, 2018 close. Since Thursday of last week IVST saw more than double average trading volume, following the StemVax announcement.
• We received notice that Winslow Asset Management registered as a shareholder, marking our first institutional shareholder position.
• We closed several key contracts with organizations ranging from local governments, to the United States Navy, University Hospitals, Cleveland Indians, University of Louisiana, Iowa Department of Transportation, Houston Metro, Tarkette and a $650K exclusive contact from Byram Healthcare, a division of a Fortune 500 Company.
• We’ve got a world-class team including two independent members of our Board of Directors, and our key corporate leadership is highlighted on our new corporate website.

Overall, Innovest Global, Inc. continues to “fire on all cylinders,” as the company’s accomplishments continue to outpace expectations. The StemVax Therapeutics acquisition effectively launched Innovest’s Biotechnology & Health Sciences division, which no doubt could see some additional acquisitions as well moving forward. StemVax’s patent award is a firm confirmation that the cancer vaccination technology is protected and ready to begin moving to the next stages of commercialization and development. This also gives Innovest Global some intellectual property to list under its assets. Innovest Global is one of the most exciting stories in the OTC Markets today. The drive and ability of management to lead the company to such impressive growth should provide shareholders with comfort of long-term potential.

Disclaimer:

Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.

All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash and fifty thousand restricted shares for the creation and dissemination of this content.

This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.

The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings.  Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.

Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com//disclosures/